BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

640 related articles for article (PubMed ID: 26169616)

  • 21. A systematic literature review of the efficacy, effectiveness, and safety of filgrastim.
    Dale DC; Crawford J; Klippel Z; Reiner M; Osslund T; Fan E; Morrow PK; Allcott K; Lyman GH
    Support Care Cancer; 2018 Jan; 26(1):7-20. PubMed ID: 28939926
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical safety of tbo-filgrastim, a short-acting human granulocyte colony-stimulating factor.
    Pettengell R; Bias P; Mueller U; Lang N
    Support Care Cancer; 2016 Jun; 24(6):2677-84. PubMed ID: 26780505
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MONITOR-GCSF DLBCL subanalysis: Treatment patterns/outcomes with biosimilar filgrastim for chemotherapy-induced/febrile neutropenia prophylaxis.
    Gascón P; Krendyukov A; Höbel N; Aapro M
    Eur J Haematol; 2018 Mar; 100(3):241-246. PubMed ID: 29171913
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of colony-stimulating factors in acute leukemia.
    Holdsworth MT; Mathew P
    Ann Pharmacother; 2001 Jan; 35(1):92-108. PubMed ID: 11197591
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Duration of filgrastim prophylaxis for chemotherapy-induced neutropenia and its predictors].
    Yang S; He X; Liu P; Zhou S; Dong M; Qin Y; Yang J; Zhang C; Han X; Shi Y
    Zhonghua Zhong Liu Za Zhi; 2016 Jan; 38(1):69-72. PubMed ID: 26796810
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim in elderly versus non-elderly cancer patients: Patterns, outcomes, and determinants (MONITOR-GCSF study).
    Aapro M; Bokemeyer C; Ludwig H; Gascón P; Boccadoro M; Denhaerynck K; Gorray M; Krendyukov A; MacDonald K; Abraham I
    J Geriatr Oncol; 2017 Mar; 8(2):86-95. PubMed ID: 27829539
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hellenic Cooperative Oncology Group.
    Skarlos DV; Timotheadou E; Galani E; Samantas E; Grimani I; Lianos E; Aravantinos G; Xanthakis I; Pentheroudakis G; Pectasides D; Fountzilas G
    Oncology; 2009; 77(2):107-12. PubMed ID: 19622901
    [TBL] [Abstract][Full Text] [Related]  

  • 28. White blood cell growth factor use in an outpatient oncology clinic: Lessons and opportunities learned.
    Le AT; Trovato JA
    J Oncol Pharm Pract; 2015 Jun; 21(3):213-9. PubMed ID: 24710955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.
    Aapro MS; Cameron DA; Pettengell R; Bohlius J; Crawford J; Ellis M; Kearney N; Lyman GH; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
    Eur J Cancer; 2006 Oct; 42(15):2433-53. PubMed ID: 16750358
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of filgrastim and pegfilgrastim to support delivery of chemotherapy: twenty years of clinical experience.
    Renwick W; Pettengell R; Green M
    BioDrugs; 2009; 23(3):175-86. PubMed ID: 19627169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of colony stimulating factors (CSFs) in solid tumours: results of an expert panel.
    Gridelli C; Aapro MS; Barni S; Beretta GD; Colucci G; Daniele B; Del Mastro L; Di Maio M; De Petris L; Perrone F; Thatcher N; De Marinis F
    Crit Rev Oncol Hematol; 2007 Jul; 63(1):53-64. PubMed ID: 17368037
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ZOHé: A Prospective Study of the Use of Biosimilar Filgrastim Zarzio in Clinical Practice in Patients Treated With Chemotherapy for Lymphoid Malignancies.
    Damaj GL; Benbrahim O; Hacini M; Voronina I; Benabed K; Soumoudronga RF; Gasnereau I; Haioun C; Solal-Céligny P
    Clin Lymphoma Myeloma Leuk; 2017 Jun; 17(6):362-369.e2. PubMed ID: 28622961
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Granulocytic growth factors and cancer-related neutropenia: limited effects.
    Prescrire Int; 2006 Oct; 15(85):189-91. PubMed ID: 17128529
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
    Rusthoven J; Bramwell V; Stephenson B
    Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Colony-stimulating factor use and impact on febrile neutropenia among patients with newly diagnosed breast, colorectal, or non-small cell lung cancer who were receiving chemotherapy.
    McCune JS; Sullivan SD; Blough DK; Clarke L; McDermott C; Malin J; Ramsey S
    Pharmacotherapy; 2012 Jan; 32(1):7-19. PubMed ID: 22392824
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Granulocyte colony-stimulating factor use in patients with chemotherapy-induced neutropenia: clinical and economic benefits.
    Rader M
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 4):16-21. PubMed ID: 16736984
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice.
    Weycker D; Li X; Barron R; Li Y; Reiner M; Kartashov A; Figueredo J; Tzivelekis S; Garcia J
    Support Care Cancer; 2016 Jun; 24(6):2481-90. PubMed ID: 26670915
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Desensitization to Filgrastim in a 2-Year-Old Girl With a Vaginal Endodermal Sinus Tumor.
    González-Cavero L; Gómez-Traseira C; Fiandor A; Entrala A; Quirce S
    J Investig Allergol Clin Immunol; 2019 Aug; 29(4):329-330. PubMed ID: 31478530
    [No Abstract]   [Full Text] [Related]  

  • 39. Compatibility of Biosimilar Filgrastim with Cytotoxic Chemotherapy during the Treatment of Malignant Diseases (VENICE): A Prospective, Multicenter, Non-Interventional, Longitudinal Study.
    Fruehauf S; Otremba B; Stötzer O; Rudolph C
    Adv Ther; 2016 Nov; 33(11):1983-2000. PubMed ID: 27743353
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Granulocyte colony--stimulating factor for chemotherapy-induced neutropenia in patients with small cell lung cancer : the 40% rule revisited.
    Calhoun EA; Schumock GT; McKoy JM; Pickard S; Fitzner KA; Heckinger EA; Powell EF; McCaffrey KR; Bennett CL
    Pharmacoeconomics; 2005; 23(8):767-75. PubMed ID: 16097839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.